To print: Select File and then Print from your browser's menu

Title: Oxymorphone Extended Release Appears Effective in Treating Patients With Chronic Low Back Pain: Presented at AAPM

"Oxymorphone Extended Release Appears Effective in Treating Patients With Chronic Low Back Pain: Presented at AAPM"

By Jerry Ingram NEW ORLEANS, LA -- February 14, 2007 -- Patients living with moderate-to-severe chronic lower back pain appear to respond well to treatment with oxymorphone hydrochloride extended release (Opana ER), according to the results of a 12-week study. Investigators presented the findings here on February 10[^th at the American Academy of Pain Medicine 23^rd Annual Meeting (AAPM).

One of the study's authors, Harry Ahdieh, PhD, director of clinical operations, Endo Pharmaceuticals Inc., Chadds Ford, Pennsylvania, reported that this 12-week randomized, double-blind, placebo-controlled trial set about to examine the efficacy of oxymorphone ER in opioid-naive patients with moderate-to-severe chronic low back pain.

For this investigation, clinicians randomized 105 patients to receive oxymorphone ER and 99 patients to receive placebo. They documented pain intensity, patient ratings of satisfaction with treatment, and adverse events for both groups.

The team analyzed the least squares mean change in pain intensity from baseline to the final visit. They found that pain intensity was significantly greater among patients on placebo compared with patients on oxymorphone ER (P < .0001).

The researchers also found that significantly more oxymorphone ER patients rated their pain medication as "good to excellent" compared with those in the placebo group (82% compared with 42%, respectively; P < .0001).

[Presentation title: Randomized, Double-Blind, Placebo-Controlled 12-Week Study Assessing the Efficacy of Oxymorphone Extended Release in Opioid-Naive Patients With Chronic Low Back Pain. Abstract 136]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.